Suppr超能文献

依非韦伦抗逆转录病毒治疗的起始与25-羟基维生素D水平降低之间的关联

Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.

作者信息

Brown Todd T, McComsey Grace A

机构信息

Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Antivir Ther. 2010;15(3):425-9. doi: 10.3851/IMP1502.

Abstract

BACKGROUND

We aimed to determine whether antiretroviral therapy (ART) initiation with efavirenz (EFV) is associated with decreases in 25-hydroxyvitamin D (25[OH]D) compared with non-EFV regimens.

METHODS

25(OH)D was measured from stored plasma samples in 87 ART-naive HIV-positive patients prior to ART initiation with EFV-containing (n=51) or non-EFV-containing (89% with protease inhibitors; n=36) regimens from a single clinic in Cleveland (OH, USA). A repeat measurement was made 6-12 months after ART initiation. The change in 25(OH)D after ART initiation and the prevalence of patients with hypovitaminosis D (< or = 37.5 nmol/l [15 ng/ml]) after ART initiation was compared in those who initiated ART with and without EFV using multivariable linear and modified Poisson regression, respectively.

RESULTS

Prior to ART initiation, the median (interquartile range [IQR]) 25(OH)D concentration was 52.7 nmol/l (IQR 32.2-72.1), with 33% prevalence of hypovitaminosis D. After 6-12 months of ART, 25(OH)D decreased by a mean +/-se of -12.7 +/-3.7 nmol/l in the EFV group relative to the non-EFV group (P=0.001) after adjustment for baseline 25(OH)D concentration, race and season (non-summer versus summer) at the visit 6-12 months after ART initiation. Similarly, after multivariable adjustment, the risk of hypovitaminosis D after ART initiation was significantly higher in the EFV group compared with the non-EFV group (prevalence ratio 1.8 [95% confidence interval 1.2-2.8]; P=0.007).

CONCLUSIONS

ART initiation with EFV is associated with significant decreases in 25(OH)D and an increased risk of hypovitaminosis D compared with non-EFV regimens.

摘要

背景

我们旨在确定与非依非韦伦(EFV)方案相比,开始使用依非韦伦(EFV)进行抗逆转录病毒治疗(ART)是否与25-羟基维生素D(25[OH]D)水平降低有关。

方法

从美国俄亥俄州克利夫兰市一家诊所的87例初治HIV阳性患者的储存血浆样本中测量25(OH)D水平,这些患者开始接受含EFV方案(n = 51)或不含EFV方案(89%使用蛋白酶抑制剂;n = 36)的ART治疗。在ART开始后6 - 12个月进行重复测量。分别使用多变量线性回归和修正泊松回归,比较开始ART治疗时使用和未使用EFV的患者在ART开始后25(OH)D的变化以及ART开始后维生素D缺乏症(<或= 37.5 nmol/l [15 ng/ml])患者的患病率。

结果

在ART开始前,25(OH)D浓度中位数(四分位间距[IQR])为52.7 nmol/l(IQR 32.2 - 72.1),维生素D缺乏症患病率为33%。在ART开始6 - 12个月后,在对ART开始后6 - 12个月就诊时的基线25(OH)D浓度、种族和季节(非夏季与夏季)进行调整后,EFV组的25(OH)D相对于非EFV组平均降低了 - 12.7 +/- 3.7 nmol/l(P = 0.001)。同样,经过多变量调整后,与非EFV组相比,EFV组在ART开始后维生素D缺乏症的风险显著更高(患病率比值1.8 [95%置信区间1.2 - 2.8];P = 0.007)。

结论

与非EFV方案相比,开始使用EFV进行ART治疗与25(OH)D显著降低以及维生素D缺乏症风险增加有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验